
Despite inflation affecting the supply chain of British American Tobacco, the company showed robust performance in the electronic cigarette and oral tobacco industry.
British American Tobacco has stated that it still expects a revenue growth of 2% to 4% by 2022, based on unchanged currency, with support from new category business including electronic cigarettes, oral products, and heated tobacco.
British American Tobacco has reported that its new category business continues to drive strong trading volume, revenue, and market share growth, making it an important contributor to the group's overall performance.
By 2025, the goal for new category businesses is to achieve a profit and revenue of £5 billion (approximately RMB 42.6 billion).
Tobacco company British American Tobacco has stated that its mid-term indicators remain unchanged. Adjusted earnings per share (excluding special items and other one-time expenses) are expected to reach the single digits by 2022.
2FIRSTS will continue to provide coverage of this issue, with updates available on the '2FIRSTS APP.' Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.









